Approval · Notice of Compliance 38419 · 2026
BILASTINE: Notice of Compliance 38419
Issued October 6, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38419
- Date
- October 6, 2026
- Company
- Sanis Health Inc.Brampton, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement between two manufacturers
- Canadian reference product
- BLEXTEN (Aralez Pharmaceuticals Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BILASTINE | 02572222 | Approved |
Medicinal ingredients
- BILASTINE 20 MG per TAB